Kostas Biliouris
Stock Analyst at BMO Capital
(0.82)
# 3,747
Out of 4,854 analysts
55
Total ratings
27.66%
Success rate
-22.21%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Kostas Biliouris
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RCKT Rocket Pharmaceuticals | Maintains: Outperform | $30 → $8 | $2.77 | +188.81% | 2 | May 28, 2025 | |
| RNA Avidity Biosciences | Initiates: Outperform | $72 | $35.59 | +102.30% | 1 | Mar 12, 2025 | |
| DYN Dyne Therapeutics | Initiates: Outperform | $50 | $13.99 | +257.40% | 1 | Mar 12, 2025 | |
| SLN Silence Therapeutics | Maintains: Outperform | $67 → $25 | $5.41 | +362.11% | 2 | Mar 4, 2025 | |
| IONS Ionis Pharmaceuticals | Maintains: Market Perform | $60 → $45 | $35.24 | +27.70% | 2 | Feb 20, 2025 | |
| NTLA Intellia Therapeutics | Maintains: Outperform | $70 → $50 | $7.58 | +559.63% | 6 | Jan 10, 2025 | |
| DTIL Precision BioSciences | Upgrades: Outperform | $34 | $5.18 | +556.37% | 3 | Jan 10, 2025 | |
| CNTA Centessa Pharmaceuticals | Maintains: Outperform | $20 → $35 | $11.86 | +195.11% | 6 | Sep 16, 2024 | |
| MGX Metagenomi | Maintains: Outperform | $22 → $17 | $1.66 | +924.10% | 2 | Aug 15, 2024 | |
| FDMT 4D Molecular Therapeutics | Maintains: Outperform | $63 → $40 | $3.91 | +923.02% | 4 | Jul 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $90 | $31.48 | +185.90% | 3 | Jul 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $234 | $308.00 | -24.03% | 4 | Jun 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $170 → $200 | $39.21 | +410.07% | 4 | Jun 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $120 | $12.48 | +861.54% | 3 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $57 | $17.00 | +235.29% | 3 | Mar 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | $37 | $38.34 | -3.50% | 1 | Jan 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $102 → $100 | $55.27 | +80.93% | 4 | Nov 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $19 | $1.36 | +1,297.06% | 1 | Oct 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $48 → $62 | $5.73 | +982.02% | 2 | Jul 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $98 | $38.57 | +154.08% | 1 | Jun 17, 2022 |
Rocket Pharmaceuticals
May 28, 2025
Maintains: Outperform
Price Target: $30 → $8
Current: $2.77
Upside: +188.81%
Avidity Biosciences
Mar 12, 2025
Initiates: Outperform
Price Target: $72
Current: $35.59
Upside: +102.30%
Dyne Therapeutics
Mar 12, 2025
Initiates: Outperform
Price Target: $50
Current: $13.99
Upside: +257.40%
Silence Therapeutics
Mar 4, 2025
Maintains: Outperform
Price Target: $67 → $25
Current: $5.41
Upside: +362.11%
Ionis Pharmaceuticals
Feb 20, 2025
Maintains: Market Perform
Price Target: $60 → $45
Current: $35.24
Upside: +27.70%
Intellia Therapeutics
Jan 10, 2025
Maintains: Outperform
Price Target: $70 → $50
Current: $7.58
Upside: +559.63%
Precision BioSciences
Jan 10, 2025
Upgrades: Outperform
Price Target: $34
Current: $5.18
Upside: +556.37%
Centessa Pharmaceuticals
Sep 16, 2024
Maintains: Outperform
Price Target: $20 → $35
Current: $11.86
Upside: +195.11%
Metagenomi
Aug 15, 2024
Maintains: Outperform
Price Target: $22 → $17
Current: $1.66
Upside: +924.10%
4D Molecular Therapeutics
Jul 18, 2024
Maintains: Outperform
Price Target: $63 → $40
Current: $3.91
Upside: +923.02%
Jul 3, 2024
Maintains: Outperform
Price Target: $90
Current: $31.48
Upside: +185.90%
Jun 24, 2024
Maintains: Outperform
Price Target: $234
Current: $308.00
Upside: -24.03%
Jun 24, 2024
Maintains: Outperform
Price Target: $170 → $200
Current: $39.21
Upside: +410.07%
May 15, 2024
Maintains: Outperform
Price Target: $120
Current: $12.48
Upside: +861.54%
Mar 27, 2024
Maintains: Outperform
Price Target: $57
Current: $17.00
Upside: +235.29%
Jan 31, 2024
Initiates: Market Perform
Price Target: $37
Current: $38.34
Upside: -3.50%
Nov 3, 2023
Maintains: Outperform
Price Target: $102 → $100
Current: $55.27
Upside: +80.93%
Oct 9, 2023
Initiates: Outperform
Price Target: $19
Current: $1.36
Upside: +1,297.06%
Jul 18, 2022
Maintains: Outperform
Price Target: $48 → $62
Current: $5.73
Upside: +982.02%
Jun 17, 2022
Initiates: Outperform
Price Target: $98
Current: $38.57
Upside: +154.08%